Straits Times Index
3,322.39 -3.89 (-0.12%) Nikkei
39,454.56 +281.41 (+0.72%) Hang Seng
17,934.63 -138.27 (-0.77%) FTSE 100
8,247.79 -33.76 (-0.41%) Bitcoin USD
61,938.08 +1,671.75 (+2.77%) CMC Crypto 200
1,285.37 +36.24 (+2.90%)
MOR Jan 2025 15.000 call
- Business Wire
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
PLANEGG/MUNICH, Germany, June 20, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG and Novartis AG hereinafter collectively referred to as "Novartis") also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a squ
- Zacks
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
- Simply Wall St.
MorphoSys (ETR:MOR) shareholders have earned a 228% return over the last year
When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
